PDCD1 and neoplasm: A study evaluating combined anti-PD-1 and TLR9 agonist immunotherapy in cardiac allograft-tolerant murine models demonstrated that intratumoral (i.t.)delivery achieved significantly greater suppression of tumor growth relative to systemic (i.p.)administration, without eliciting accelerated allograft rejection (26).